pirfenidone has been researched along with Congestive Ophthalmopathy in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hou, TY; Kau, HC; Tsai, CC; Wu, SB | 1 |
| Back, KO; Choi, YH; Kim, HJ; Kook, KH; Lee, SY | 1 |
| Back, KO; Choi, YH; Chung, SA; Jeon, BK; Kook, KH; Lee, JB | 1 |
| Choi, YH; Jou, I; Kim, H; Kim, SJ; Kook, KH; Lee, SY; Park, SJ | 1 |
| Fratianni, C; Gonzales, M; Khardori, R; Mamillapali, C | 1 |
1 review(s) available for pirfenidone and Congestive Ophthalmopathy
| Article | Year |
|---|---|
Immunotherapy in miscellaneous medical disorders Graves ophthalmopathy, asthma, and regional painful syndrome.
Topics: Allergens; Anti-Asthmatic Agents; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antioxidants; Asthma; Azathioprine; Benzamides; Complex Regional Pain Syndromes; Cyclosporine; Decompression, Surgical; Etanercept; Glucocorticoids; Graves Ophthalmopathy; Humans; Imatinib Mesylate; Immunoglobulin G; Immunoglobulins, Intravenous; Immunosuppressive Agents; Immunotherapy; Octreotide; Omalizumab; Orbit; Piperazines; Pyridones; Pyrimidines; Radiotherapy Dosage; Receptors, Tumor Necrosis Factor; Risk Factors; Rituximab; Selenium | 2012 |
4 other study(ies) available for pirfenidone and Congestive Ophthalmopathy
| Article | Year |
|---|---|
Effect of Pirfenidone on TGF-β1-Induced Myofibroblast Differentiation and Extracellular Matrix Homeostasis of Human Orbital Fibroblasts in Graves' Ophthalmopathy.
Topics: Actins; Cell Differentiation; Collagen Type I; Connective Tissue Growth Factor; Extracellular Matrix; Fibroblasts; Fibronectins; Gene Expression Regulation; Graves Ophthalmopathy; Homeostasis; Humans; Matrix Metalloproteinases; Myofibroblasts; Primary Cell Culture; Pyridones; Tissue Inhibitor of Metalloproteinases; Transforming Growth Factor beta1 | 2021 |
Pirfenidone attenuates IL-1β-induced COX-2 and PGE2 production in orbital fibroblasts through suppression of NF-κB activity.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cells, Cultured; Cyclooxygenase 2; Dinoprostone; Drug Synergism; Electrophoretic Mobility Shift Assay; Enzyme-Linked Immunosorbent Assay; Female; Fibroblasts; Gene Expression Regulation; Graves Ophthalmopathy; Humans; Interleukin-1beta; Male; Middle Aged; NF-kappa B; Orbit; Pyridones; Real-Time Polymerase Chain Reaction; Receptors, Interleukin-1 Type I; RNA, Messenger | 2013 |
Pirfenidone attenuates the IL-1β-induced hyaluronic acid increase in orbital fibroblasts from patients with thyroid-associated ophthalmopathy.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Fibroblasts; Gene Expression Regulation; Glucuronosyltransferase; Graves Ophthalmopathy; Humans; Hyaluronan Synthases; Hyaluronic Acid; Interleukin-1beta; Male; Middle Aged; Pyridones; Real-Time Polymerase Chain Reaction; RNA; Tumor Necrosis Factor-alpha | 2014 |
Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cell Culture Techniques; Cell Survival; Collagen; Dexamethasone; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Fibroblasts; Graves Ophthalmopathy; Humans; Hydroxyproline; Intercellular Signaling Peptides and Proteins; Interleukin-1beta; Male; Middle Aged; Orbit; Pyridones; Tissue Inhibitor of Metalloproteinase-1; Tumor Necrosis Factor-alpha; Young Adult | 2010 |